This report contains market size and forecasts of Acute Myeloid Leukemia (AML) Biomarker Testing in Global, including the following market information:
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Acute Myeloid Leukemia (AML) Biomarker Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Genetic Acute Myeloid Leukemia (AML) Biomarker Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Acute Myeloid Leukemia (AML) Biomarker Testing include Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc., Sysmex Corporation, Epigenomics AG, BioMerieux SA and Skyline DX B.V., etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Acute Myeloid Leukemia (AML) Biomarker Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Segment Percentages, by Type, 2022 (%)
Genetic Acute Myeloid Leukemia (AML) Biomarker
Epigenetic Acute Myeloid Leukemia (AML) Biomarker
Proteomic Acute Myeloid Leukemia (AML) Biomarker
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Segment Percentages, by Application, 2022 (%)
Hospitals
Cancer diagnostic Centers
Research Institutes
Others
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Myeloid Leukemia (AML) Biomarker Testing revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Acute Myeloid Leukemia (AML) Biomarker Testing revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott Laboratories
Novartis AG
Thermo Fisher Scientific
Cancer Genetics Inc.
Sysmex Corporation
Epigenomics AG
BioMerieux SA
Skyline DX B.V.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Acute Myeloid Leukemia (AML) Biomarker Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Overall Market Size
2.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size: 2022 VS 2030
2.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Acute Myeloid Leukemia (AML) Biomarker Testing Players in Global Market
3.2 Top Global Acute Myeloid Leukemia (AML) Biomarker Testing Companies Ranked by Revenue
3.3 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue by Companies
3.4 Top 3 and Top 5 Acute Myeloid Leukemia (AML) Biomarker Testing Companies in Global Market, by Revenue in 2022
3.5 Global Companies Acute Myeloid Leukemia (AML) Biomarker Testing Product Type
3.6 Tier 1, Tier 2 and Tier 3 Acute Myeloid Leukemia (AML) Biomarker Testing Players in Global Market
3.6.1 List of Global Tier 1 Acute Myeloid Leukemia (AML) Biomarker Testing Companies
3.6.2 List of Global Tier 2 and Tier 3 Acute Myeloid Leukemia (AML) Biomarker Testing Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size Markets, 2022 & 2030
4.1.2 Genetic Acute Myeloid Leukemia (AML) Biomarker
4.1.3 Epigenetic Acute Myeloid Leukemia (AML) Biomarker
4.1.4 Proteomic Acute Myeloid Leukemia (AML) Biomarker
4.2 By Type - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue & Forecasts
4.2.1 By Type - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2023
4.2.2 By Type - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2023-2030
4.2.3 By Type - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Cancer diagnostic Centers
5.1.4 Research Institutes
5.1.5 Others
5.2 By Application - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue & Forecasts
5.2.1 By Application - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2023
5.2.2 By Application - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2023-2030
5.2.3 By Application - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2022 & 2030
6.2 By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue & Forecasts
6.2.1 By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2023
6.2.2 By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2023-2030
6.2.3 By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2030
6.3.2 US Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.3.3 Canada Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.3.4 Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2030
6.4.2 Germany Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.4.3 France Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.4.4 U.K. Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.4.5 Italy Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.4.6 Russia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.4.7 Nordic Countries Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.4.8 Benelux Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2030
6.5.2 China Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.5.3 Japan Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.5.4 South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.5.5 Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.5.6 India Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2030
6.6.2 Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.6.3 Argentina Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2030
6.7.2 Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.7.3 Israel Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.7.4 Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
6.7.5 UAE Acute Myeloid Leukemia (AML) Biomarker Testing Market Size, 2018-2030
7 Players Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Corporate Summary
7.1.2 Abbott Laboratories Business Overview
7.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.1.4 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.1.5 Abbott Laboratories Key News
7.2 Novartis AG
7.2.1 Novartis AG Corporate Summary
7.2.2 Novartis AG Business Overview
7.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.2.4 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.2.5 Novartis AG Key News
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Corporate Summary
7.3.2 Thermo Fisher Scientific Business Overview
7.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.3.4 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.3.5 Thermo Fisher Scientific Key News
7.4 Cancer Genetics Inc.
7.4.1 Cancer Genetics Inc. Corporate Summary
7.4.2 Cancer Genetics Inc. Business Overview
7.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.4.4 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.4.5 Cancer Genetics Inc. Key News
7.5 Sysmex Corporation
7.5.1 Sysmex Corporation Corporate Summary
7.5.2 Sysmex Corporation Business Overview
7.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.5.4 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.5.5 Sysmex Corporation Key News
7.6 Epigenomics AG
7.6.1 Epigenomics AG Corporate Summary
7.6.2 Epigenomics AG Business Overview
7.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.6.4 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.6.5 Epigenomics AG Key News
7.7 BioMerieux SA
7.7.1 BioMerieux SA Corporate Summary
7.7.2 BioMerieux SA Business Overview
7.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.7.4 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.7.5 BioMerieux SA Key News
7.8 Skyline DX B.V.
7.8.1 Skyline DX B.V. Corporate Summary
7.8.2 Skyline DX B.V. Business Overview
7.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Major Product Offerings
7.8.4 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global Market (2018-2023)
7.8.5 Skyline DX B.V. Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Acute Myeloid Leukemia (AML) Biomarker Testing Market Opportunities & Trends in Global Market
Table 2. Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers in Global Market
Table 3. Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints in Global Market
Table 4. Key Players of Acute Myeloid Leukemia (AML) Biomarker Testing in Global Market
Table 5. Top Acute Myeloid Leukemia (AML) Biomarker Testing Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Share by Companies, 2018-2023
Table 8. Global Companies Acute Myeloid Leukemia (AML) Biomarker Testing Product Type
Table 9. List of Global Tier 1 Acute Myeloid Leukemia (AML) Biomarker Testing Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Acute Myeloid Leukemia (AML) Biomarker Testing Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2023-2030
Table 30. Abbott Laboratories Corporate Summary
Table 31. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 32. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
Table 33. Novartis AG Corporate Summary
Table 34. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 35. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
Table 36. Thermo Fisher Scientific Corporate Summary
Table 37. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 38. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
Table 39. Cancer Genetics Inc. Corporate Summary
Table 40. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 41. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
Table 42. Sysmex Corporation Corporate Summary
Table 43. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 44. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
Table 45. Epigenomics AG Corporate Summary
Table 46. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 47. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
Table 48. BioMerieux SA Corporate Summary
Table 49. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 50. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
Table 51. Skyline DX B.V. Corporate Summary
Table 52. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Product Offerings
Table 53. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Acute Myeloid Leukemia (AML) Biomarker Testing Segment by Type in 2022
Figure 2. Acute Myeloid Leukemia (AML) Biomarker Testing Segment by Application in 2022
Figure 3. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Acute Myeloid Leukemia (AML) Biomarker Testing Revenue in 2022
Figure 8. By Type - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 9. By Application - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 10. By Region - Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 11. By Country - North America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 12. US Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 16. Germany Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 17. France Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 24. China Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 28. India Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 30. Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Market Share, 2018-2030
Figure 33. Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, (US$, Mn), 2018-2030
Figure 37. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
